Ashok Kumar Sah^1,*, Ranjay Kumar Choudhary^1,2, Velilyaeva Alie Sabrievna³, Karomatov Inomdzhon Dzhuraevich⁴, Anass M. Abbas⁵, Manar G. Shalabi⁵, Nadeem Ahmad Siddique⁶, Raji Rubayyi Alshammari⁷, Navjyot Trivedi⁸, Rabab H. Elshaikh¹

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.068238 - 30 December 2025

Abstract Male breast cancer (MBC) is rare, representing 0.5%–1% of all breast cancers, but its incidence is increasing due to improved diagnostics and awareness. MBC typically presents in older men, is human epidermal growth factor receptor 2 (HER2)-negative and estrogen receptor (ER)-positive, and lacks routine screening, leading to delayed diagnosis and advanced disease. Major risk factors include hormonal imbalance, radiation exposure, obesity, alcohol use, and Breast Cancer Gene 1 and 2 (BRCA1/2) mutations. Clinically, it may resemble gynecomastia but usually appears as a unilateral, painless mass or nipple discharge. Advances in imaging and liquid biopsy have More >

Amber Hassan¹, Badr Hafiz², Taghreed Alsinani³, Rakan Bokhari⁴, Dahlia Mirdad⁵, Awab Tayyib⁵, Alaa Alkhotani⁶, Ahmad Fallata⁷, Iman Mirza⁸, Eyad Faizo^9,10, Saleh Baeesa², Huda Alghefari¹¹, Maher Kurdi^11,*

Oncology Research, Vol.33, No.11, pp. 3293-3325, 2025, DOI:10.32604/or.2025.070031 - 22 October 2025

Abstract Background: Glioblastoma (GBM) remains the most aggressive primary brain tumour in adults, marked by pronounced cellular heterogeneity, diffuse infiltration, and resistance to conventional treatment. In recent years, transcriptomic profiling has provided valuable insights into the molecular mechanisms that govern the progression of glioblastoma. This systematic review aims to synthesise the current literature on dysregulated gene expression in GBM, focusing on gene signatures associated with stemness, immune modulation, extracellular matrix remodelling, metabolic adaptation, and therapeutic resistance. Methods: We conducted a systematic search of PubMed, The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and the GlioVis… More >

Matthew Rubinstein^1,*, Madeline Lauren Hong¹, Rishi Kumar Nanda¹, Daniel Thomas Jones¹, Hazem Aboaid², Yin Mon Myat³, Kyaw Zin Thein⁴

Oncology Research, Vol.33, No.11, pp. 3161-3183, 2025, DOI:10.32604/or.2025.067791 - 22 October 2025

Abstract The ever-expanding development of tissue-agnostic therapies which target malignancies based on specific mutations rather than tissue origin have transformed the landscape of oncology. The purpose of this review is to explore the impact, safety, and challenges of tissue-agnostic therapies including pembrolizumab, dostarlimab, larotrectinib, entrectinib, repotrectinib, dabrafenib plus trametinib, selpercatinib, and trastuzumab deruxtecan. As the therapeutic arsenal continues to grow, it is crucial to understand how these therapies truly benefit patients and to address the barriers that stand in the way of making them more widely available. Although these therapies have shown effectiveness across multiple cancer More >

HAFIZ MUHAMMAD REHMAN^1,2,*, SIDRA AHMAD², AZEEM SARWAR¹, HAMID BASHIR^2,*

Oncology Research, Vol.33, No.7, pp. 1547-1570, 2025, DOI:10.32604/or.2025.062197 - 26 June 2025

Abstract Targeted cancer therapy has emerged as a promising alternative to conventional chemotherapy, which is often plagued by poor selectivity, off-target effects, and drug resistance. Among the various targeting agents in development, peptides stand out for their unique advantages, including minimal immunogenicity, high tissue penetration, and ease of modification. Their small size, specificity, and flexibility allow them to target cancer cells while minimizing damage to healthy tissue selectively. Peptide-based therapies have shown great potential in enhancing the efficacy of drug delivery, improving tumor imaging, and reducing adverse effects. With cancer responsible for millions of deaths worldwide,… More >

YUZHI LIU^1,#, EVELYNE BISCHOF^2,#, ZHIQIN CHEN¹, JIAHUAN ZHOU³, BEI ZHANG⁴, DING ZHANG⁴, YONG GAO^1,*, MING QUAN^1,*

Oncology Research, Vol.32, No.9, pp. 1429-1438, 2024, DOI:10.32604/or.2024.047309 - 23 August 2024

Abstract Objectives: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have demonstrated potential benefits for metastatic colorectal cancer (mCRC) patients with HER2 amplification, but are not satisfactory in cases of HER2 mutant CRCs. Methods: Consequently, further elucidation of amplifications and somatic mutations in erythroblastic oncogene B-2 (ERBB2) is imperative. Comprehensive genomic profiling was conducted on 2454 Chinese CRC cases to evaluate genomic alterations in 733 cancer-related genes, tumor mutational burden, microsatellite instability, and programmed death ligand 1 (PD-L1) expression. Results: Among 2454 CRC patients, 85 cases (3.46%) exhibited ERBB2 amplification, and 55 cases (2.24%) carried ERBB2 mutation.… More > Graphic Abstract